SCHEMBL126286

SCHEMBL126286

CCOc1cccc([CH]O)c1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.61
ALDH1A1 P00352 1/20 0.61
SMN1; SMN2 Q16637 1/20 0.61
TP53 P04637 1/20 0.53
CYP3A4 P08684 1/20 0.53
RELA Q04206 1/20 0.47
RXRA P19793 1/20 0.45
RXRB P28702 1/20 0.45
MAPK1 P28482 2/20 0.43
LMNA P02545 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
NQO1 P15559 1/20 0.43
CYP1A2 P05177 1/20 0.42
CYP2D6 P10635 1/20 0.42
CYP2C19 P33261 1/20 0.42
LTA4H P09960 1/20 0.42
ESR1 P03372 2/20 0.42
AHR P35869 1/20 0.42
TLR4 O00206 1/20 0.42
TLR2 O60603 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16958381 0.85 KMT2A (0.54) KDM4EALDH1A1SMN1; SMN2LMNALTA4H
SCHEMBL5247739 0.84 KDM4E (0.60) KDM4EALDH1A1SMN1; SMN2TP53CYP3A4
SCHEMBL16951555 0.84 TLR4 (0.60) LTA4HAHRTLR4TLR2THRB
SCHEMBL3197074 0.82 KDM4E (0.58) KDM4EALDH1A1SMN1; SMN2TP53CYP3A4
SCHEMBL28005738 0.81 TSHR (0.59) LTA4HTLR4TLR2THRBKMT2A
SCHEMBL410570 0.81 KDM4E (0.57) KDM4EALDH1A1SMN1; SMN2TP53CYP3A4
SCHEMBL29432706 0.81 MAOA (0.62) KDM4EALDH1A1SMN1; SMN2TP53CYP3A4
SCHEMBL694325 0.81 KDM4E (0.57) KDM4EALDH1A1SMN1; SMN2TP53CYP3A4
SCHEMBL493931 0.81 MAOA (0.62) KDM4EALDH1A1SMN1; SMN2TP53CYP3A4
SCHEMBL16957497 0.80 FURIN (0.48) KDM4EALDH1A1SMN1; SMN2MAPK1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2900645-A1 3-PHENYLISOXAZOLIN DERIVATIVES WITH HERBICIDAL ACTION Bayer CropScience AG (DE) 2015-08-05 EP disclosed
US-8450319-B2 Pyrrolopyridazinone compound UBE INDUSTRIES, LTD. (JP) 2013-05-28 US disclosed
EP-1982986-B1 PYRROLOPYRIDAZINONE COMPOUND AS PDE4 INHIBITOR UBE INDUSTRIES (JP) 2012-03-07 EP disclosed
CN-101374844-A Pyrrolopyridazinone compound UBE INDUSTRIES (JP) 2009-02-25 CN disclosed
US-20090036453-A1 Pyrrolopyridazinone Compound UBE INDUSTRIES, LTD. (JP) 2009-02-05 US disclosed
EP-1982986-A1 PYRROLOPYRIDAZINONE COMPOUND Ube Industries, Ltd. (JP) 2008-10-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090036453-A1 Pyrrolopyridazinone Compound CBR3, CBR1, CYC1 KDM4E 1902/4885ALDH1A1 580/4885SMN1; SMN2 4613/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.